Kenvue Reports $0.76 FY2025 EPS, Announces $250M Restructuring Plan

Kenvue Inc. (NYSE: KVUE) reported fiscal 2025 earnings per share of $0.76, supported by net income of $1.47 billion for the year ended December 28, 2025. The consumer health giant, which houses brands like Tylenol, Listerine, and Band-Aid, simultaneously announced a significant restructuring program aimed at transforming its operations.

Key Numbers

The company's full-year earnings of $0.76 per share reflected a challenging operating environment in the consumer health sector. Net income for fiscal 2025 totaled $1.47 billion, with quarterly performance showing some volatility throughout the year. The fourth quarter results, while not fully detailed in the filing, capped a year where third-quarter earnings came in at $0.21 per share on $400 million in net income.

The quarterly progression tells an important story about Kenvue's performance trajectory. After generating $0.39 per share in the second quarter on $740 million of net income, the company saw a significant sequential decline in Q3 to $0.21 per share. This 46% quarter-over-quarter drop in earnings highlighted operational pressures that likely influenced management's decision to pursue aggressive restructuring.

Perhaps the most significant financial disclosure was the $250 million restructuring charge expected in fiscal 2026. This substantial investment represents approximately 17% of the company's fiscal 2025 net income, underscoring management's commitment to operational transformation. The restructuring costs break down into three main categories: information technology and project-related costs will consume roughly $148 million (59%), employee-related expenses will total about $88 million (35%), and other implementation costs will account for approximately $15 million (6%).

What Management Said

Kenvue's Board of Directors approved the restructuring initiative on February 17, 2026, positioning it as a comprehensive effort to "optimize its operating model, transform its supply chain, reduce complexity, and drive operational efficiencies." The language suggests management sees structural challenges that require more than incremental adjustments.

The planned 3.5% net global workforce reduction signals a meaningful but measured approach to rightsizing the organization. For context, if Kenvue employs approximately 23,000 people globally (typical for a company of its size), this would impact roughly 800 positions. Management emphasized that the initiative aims to strengthen core capabilities while driving efficiencies, suggesting a strategic reallocation of resources rather than simple cost-cutting.

The company acknowledged uncertainty in its restructuring estimates, noting that actual charges could differ materially from projections due to factors including local law requirements in various jurisdictions. This cautionary language reflects the complexity of executing global workforce reductions, particularly in markets with strong labor protections.

Management also warned about execution risks, specifically highlighting concerns that the company might not realize the full amount of estimated savings or that costs could exceed forecasts. These forward-looking statement caveats suggest the restructuring plan remains in early stages with significant implementation challenges ahead.

What to Watch

Investors should monitor several key metrics as Kenvue executes its transformation plan throughout fiscal 2026. The immediate focus will be on whether the company can stabilize its quarterly earnings trajectory after the volatility seen in 2025. The sharp decline from Q2 to Q3 2025 raises questions about underlying business momentum that restructuring alone may not address.

The technology-heavy nature of the restructuring spend (59% of total costs) suggests Kenvue is pursuing digital transformation alongside workforce optimization. Success will likely be measured not just in cost savings but in improved operational metrics like inventory turnover, order fulfillment rates, and supply chain efficiency. These investments typically take 12-18 months to generate meaningful returns.

Execution risk remains paramount. The company's explicit warnings about potential disruptions to business operations during the restructuring period merit close attention. Any signs of market share loss or customer service degradation during the transition could offset anticipated benefits. Historical precedents from similar consumer goods restructurings suggest that maintaining sales momentum while reducing complexity presents significant challenges.

The timing of this announcement, coming alongside fourth-quarter results, positions fiscal 2026 as a transitional year for Kenvue. Investors should expect continued volatility in quarterly results as restructuring charges flow through the income statement. The true test will come in fiscal 2027, when the company should begin demonstrating whether the $250 million investment delivers sustainable margin expansion and competitive advantages in an increasingly challenging consumer health market.

*Source: Kenvue Inc. Form 8-K filed with the SEC on February 17, 2026*

— StockCliff Research